1 min read|56 words
BIO 2026 conference in San Diego revealed biotech industry's dual focus on AI-driven drug development and navigating federal regulatory uncertainty. Industry leaders expressed cautious optimism despite macroeconomic headwinds, with particular emphasis on AI applications in drug discovery and clinical trial design. Read the full analysis from STAT News coverage.
Read the full article on GMJ Newsroom →
Was this article helpful?
